Bone Lesion Found in 38-Year-Old Woman

Poll

A 38-year-old woman with a history of hyperparathyroidism presents with a lesion in the left humerus bone. What is your diagnosis?

A 38-year-old woman with a history of hyperparathyroidism presents with a lesion in the left humerus bone. According to the pathology slide, what is your diagnosis?

What is your diagnosis?

A. Metastatic adenocarcinoma
B. Osteosarcoma
C. Giant cell tumor of hyperparathyroidism
D. Granulomatous reaction
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC

Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC

Jason M. Broderick
October 18th 2025
Article

The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Adjuvant T-DXd Improves Efficacy vs T-DM1 in HER2-Positive Breast Cancer

Ashling Wahner
October 18th 2025
Article

T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

Tim Cortese
October 18th 2025
Article

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

Russ Conroy
October 18th 2025
Article

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.